Floatz logo

Sorafenib

Renal Cell Carcinoma

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoSmall moleculePhase 4 / ApprovedDormant
BBB
79/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
72/ 100
Competitive Position
89/ 100

Competitive context

271 Active assets in the Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pazopanib
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Cyclosporin A
National Cancer Institute (NCI)
Phase 2BB
INTERFERON-ALFA-2A
Central European Society for Anticancer Drug Research
Phase 3BB
Everolimus
Merck Sharp & Dohme LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Sorafenib is also rated in:

portal vein thrombosisDormant
BBB
Indicative · Phase 4
74 / 100
View asset →
adult hepatocellular carcinomaDormant
BBB
Indicative · Phase 3
73 / 100
View asset →
gliosarcomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →